Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSneha RathiVSVanessa SchmittHBHeiko Babel

Discussion

Loading...

Member takes

Overview

Population pharmacokinetics and clinical data show re-administering etentamig after delays does not require a step-up dose.

Key Points

  • To evaluate the effects of dosing delays on the pharmacokinetics and safety of etentamig treatment in patients with relapsed/refractory multiple myeloma.
  • Utilized a population pharmacokinetics model to simulate serum concentration profiles after etentamig dosing.
  • Analyzed clinical data from a phase 1b study for dosing delays and observed events like Cytokine release syndrome.
  • Conducted pharmacokinetic/pharmacodynamic simulations to assess IL-6 levels after dosing interruptions.
  • Predicted mean etentamig concentrations were found to drop below threshold after 16 weeks, increasing to 24 weeks at steady state.
  • IL-6 levels upon therapy restart were lower than those observed with the reference regimen.
  • No recurrent Cytokine release syndrome events were noted beyond Cycle 1, with maximum dosing delays of up to 68 days observed.

Cite This Study

Rathi et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df3bhttps://doi.org/10.1182/blood-2025-2266
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses2025
  2. 2Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study2025 · 2 citations
  3. 3Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.2026
  4. 4Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis2025 · 3 citations
  5. 5Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma2026